New obesity drug tested in kidney patients – safety first

NCT ID NCT07443059

First seen Mar 10, 2026 · Last updated May 14, 2026 · Updated 6 times

Summary

This study looks at how a single shot of ZT002 (zovaglutide) behaves in the body and its safety in 40 adults with varying kidney function, including those with normal kidneys. Participants are overweight or obese and have stable chronic kidney disease. The goal is to understand how the drug is processed, not to treat the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital Of Shandong First Medical Unversity

    RECRUITING

    Jinan, Shandong, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xiamen University

    NOT_YET_RECRUITING

    Xiamen, Fujian, 361003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.